9月9日 - ** 制药公司Ionis Pharmaceuticals IONS.O 股价盘前上涨2%，报62.21美元。
** IONS称，美国FDA已授予其实验性药物ION582 "突破性疗法 "称号，用于治疗一种名为 "安杰曼综合征 "的罕见神经系统疾病。
** AS是一种罕见的遗传性疾病，主要影响神经系统，其特征是发育迟缓、语言障碍和性格开朗。
** 美国食品和药物管理局（FDA）的标签旨在加快开发和审查治疗严重疾病或未满足医疗需求的药物
** IONS表示已于今年早些时候开始ION582的后期研究
** 截至上次收盘，股价累计上涨74.5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.